UNSPSC 51152013: Cinflumide

This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0XVL451MO. European Medicines Agency schedules Cinflumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06296MIG. Cinflumide generally arises in the molecular formula C12H12FNO.

The term CINFLUMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) CINFLUMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinflumide under HS 29242995 and SITC 51479. As of Q4 2014, CINFLUMIDE remains the US FDA Preferred Term for this commodity. Cinflumide bears US NLM identifiers UMLS ID C1880086 and NCI Concept Code C65330. SMILES: C1CC1NC(=O)/C=C/C2=CC(=CC=C2)F.

UNSPSC 51152013 Cinflumide is a Commodity code that captures pharmaceutical products and related delivery systems procured by state and local health agencies, specifically naloxone (opioid reversal medication) and drug deactivation systems. State and local governments buy these products to support community health and emergency response initiatives, with procurement routed through county health departments and state health and human services commissions. Issuing bodies include county health authorities and state-level health agencies managing pharmacy benefit programs and community health delivery. The work involves competitive bidding for pharmaceutical supplies with recurring annual demand, fixed-fee pricing, quarterly or ongoing delivery cycles, and compliance with federal regulations when FEMA or other federal funding sources underwrite the procurement.

Recent activity centers in Florida and Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline, requiring quarterly delivery to the county community health building and electronic submission through the county's e-procurement portal. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation exploring direct-to-manufacturer prescription fulfillment capabilities and vendor experience with self-insured employer and government health plans, designed to inform future formal procurement strategy before a formal RFP is released. Both opportunities stress vendor compliance with federal workplace and environmental regulations, insurance and liability coverage, and E-Verify employment verification where applicable.